| arznei-telegramm® 02/2017 |
SPOT ON |
| Post-marketing trials without tangible benefit |
NEW ON THE MARKET |
| Anti-interleukin-5 antibody reslizumab (CINQAERO) for severe eosinophilic asthma |
THERAPY FROM A CRITICAL VIEWPOINT |
| Delirium in palliative care: neuroleptics worse than placebo |
| Tapentadol (PALEXIA, YANTIL): What |
IN BRIEF |
| Migraine prevention in children: is placebo the best medicine? |
| Death following overdose of colchicine - the package size of the drop formulation is to be limited |
| France: zolpidem (STILNOX, generics) -narcotic prescription required |
| Glucosamine and chondroitin in osteoarthritis without benefit in yet another study |
CURRENT ADR NETWORK REPORT |
| Urticaria with apixaban (ELIQUIS) |
SIDE EFFECTS |
| Malformations with hydroxyethylrutoside (e.g. VENORUTON)? |
| Fatalities with selexipag (UPTRAVI) in pulmonary hypertension | Rivaroxaban (XARELTO): agranulocytosis and STEVENS-JOHNSON syndrome |
e a-t ON THE INTERNET |
| Elbasvir plus Grazoprevir (ZEPATIER) for hepatitis C |
| Amputations with SGLT2 inhibitors |
| Once more: anaphylactic reactions with chlorhexidine |